AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00894322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once weekly
Description: subcutaneous injection, 10.0 mg, single injection
Study NCT00894322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once weekly
Description: subcutaneous injection, 2.0 mg, once a week for 12 weeks
Study NCT00894322 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection, volume equivalent to Cohort 2 experimental intervention, once a week for 12 weeks
Study NCT03522974 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Strawberry powder
Description: Freeze dried strawberry powder
Study NCT03522974 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Strawberry powder
Description: Freeze dried strawberry powder
Study NCT03522974 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: 40 g/d placebo powder matched for taste and appearance
Study NCT04650802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait training
Description: Participants receive five weeks individual robotic gait training in LOPES II, targeting paretic propulsion (60 minutes, two time a week). The robotic gait training is complemented with daily home exercises (15 minutes/day) focusing on increasing strength and practice of learned strategies in daily life.
Study NCT03194698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light Treatment (IPL)
Description: IPL is a high-intensity light source consisting of visible light in the wavelength range of 515-1200 nm, that is aimed at the eyes. Treatments are spaced four to six weeks apart for a total of 4 treatments.
Study NCT03194698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meibomian Gland Expression
Description: Manual expression of the meibomian glands by placing the thumb against the lid margin and press firmly against the eyeball to determine the percentage of meibomian pores that are blocked. This assessment is performed on both the upper and lower lid of each eye.
Study NCT03194698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Meibomian Gland Expression
Description: Manual expression of the meibomian glands by placing the thumb against the lid margin and press firmly against the eyeball to determine the percentage of meibomian pores that are blocked. This assessment is performed on both the upper and lower lid of each eye.
Study NCT02484742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insomnia symptom induction
Description: Several nights during the 18-day stay will be disrupted, such that we delay sleep onset, advance sleep off set, and the sleep period will be disrupted by frequent nighttime awakenings.
Study NCT04946539 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: Enthesitis assessment via ultrasonography
Study NCT04208594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: comparing between both drugs for the effect of hypotensive anesthesia
Study NCT04208594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: comparing between both drugs for the effect of hypotensive anesthesia
Study NCT03195543 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet function analyzer-100
Description: The PFA-100 system evaluates primary hemostasis in whole blood samples.
Study NCT03195543 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Light transmission aggregometry
Description: Light transmission aggregometry is the gold standard method for assessing platelet function.
Study NCT03195543 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rotational thromboelastometry
Description: ROTEM is a viscoelastic method for hemostasis testing in whole blood.This assay investigates the interaction of blood cells, coagulation factors and their inhibitors during clotting and subsequent fibrinolysis.
Study NCT03195543 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endogenous thrombin potential
Description: The endogenous thrombin potential assesses the amount of thrombin which can be generated after the in vitro activation of coagulation and represents the balance between pro- and anti-coagulant forces in plasma.
Study NCT03659591 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behaviour Therapy
Description: CBT will be delivered in group format, consisting of 10 weekly two-hour sessions, with 10 participants per group
Study NCT03659591 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive Psychological Training
Description: APT will be delivered in group format, consisting of 5 weekly two-hour sessions, with 20 participants per group
Study NCT01687959 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tissue sampling from peritoneum of the gallbladder
Description: tissue sampling from peritoneum of the gallbladder during laparoscopic cholecystectomy after an acute attack of acute biliary pancreatitis
Study NCT02605707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous stem cell transplantation
Description: Intravenous injection of autologous endothelial progenitor cells transplantation
Study NCT02945033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin intake
Description: Patient with colonic adenocarcinoma stage III or II high risk will take aspirin 100 mg/day during 3 years
Study NCT02945033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo intake
Description: Patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years
Study NCT02945033 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection of colonic adenocarcinoma stage III or II high risk
Description: Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines
Study NCT02945033 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgical resection of colonic adenocarcinoma stage III or II high risk
Description: Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines
Study NCT02945033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Molecular analysis of exon 9 and 20 of PI3K
Description: Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece
Study NCT02945033 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Molecular analysis of exon 9 and 20 of PI3K
Description: Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece
Study NCT02945033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood intake
Description: Blood intake will be done every 6 months to evaluate patient compliance to treatment
Study NCT02945033 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: blood intake
Description: Blood intake will be done every 6 months to evaluate patient compliance to treatment
Study NCT01834014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT01834014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT01834014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-OHP
Description: 85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT01834014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-OHP
Description: 85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT01834014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: l-LV
Description: 200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT01834014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: l-LV
Description: 200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT01834014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT01834014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT01834014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT00334360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No drugs given during controlled hypothermia
Study NCT01711281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracardiac Impedance Measurement Algorithm (integrated in CRT-D device)
Study NCT01834014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT02090647 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aesthetic outcome
Study NCT03939663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: starch pills manufactured to mimic misoprostol 200 mg tablets
Study NCT03131804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradialytic aerobic low intensity exercise
Description: Intradialytic aerobic low intensity exercise program of 45 minutes per each hemodialysis session throughout the 6-month study duration
Study NCT04290143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colored healing water
Description: Patients will be treated with colored healing water for 20 minutes.
Study NCT04385667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel intrauterine system (LNG-IUD)
Description: progestin delivery for regression of atypical endometrial hyperplasia
Study NCT04385667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Megesterol 160 mg daily
Description: progestin delivery for regression of atypical endometrial hyperplasia
Study NCT04252924 — intervention group
Intervention type: OTHER
Intervention: lifestyle characteristics
Description: Exposures of interest: Mediterranean diet, orthorexia nervosa, smoking, physical activity, sleep duration, stress level
Study NCT05823389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Re-instrumentation with flapless Emdogain application
Description: Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive flapless administration of EMD
Study NCT05823389 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Re-instrumentation with placebo application
Description: Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive placebo application
Study NCT04236440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116 (A1)
Description: 160 μg BAY2586116 (nasal spray administration)
Study NCT04236440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (A2)
Description: Placebo matching BAY2586116 (nasal spray administration)
Study NCT04236440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116 (B1)
Description: 160 μg BAY2586116 (nasal drops)
Study NCT03372252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: Simplified electroencephalography using three electroencephalogram electrodes and two electro-oculogram electrodes for the measurement of central respiratory control through the inspiratory premotor potentials.
Study NCT04497545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luna EMG
Description: The duration of the overall therapeutic intervention in both groups will be the same.
Study NCT04497545 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: lower limb rotor
Description: The duration of the overall therapeutic intervention in both groups will be the same.
Study NCT01052766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT and BH PET/CT
Description: First, fiducial markers will be placed and taped on the patient's lower chest/upper abdomen. This will allow for monitoring of chest motion during breathing. A BH-CT scan will then be acquired with clinical CT scan parameters used in nuclear medicine. A BH-PET scan (acquisition time: 6 min per bed position) will follow the BH-CT scan. BH-PET images will cover the whole thorax, which, on average, corresponds to 1-3 PET FOV's (\~15 cm/FOV). Data for these 1-3 bed positions are acquired to cover the entire thorax. There will be no additional radiotracer injection for the BH-PET scan.
Study NCT04923724 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tourniquet
Description: tourniquet is a device used during total knee surgery.
Study NCT04923724 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No tourniquet
Description: tourniquet is a device used during total knee surgery, this group does not get one
Study NCT01414764 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous conditioned plasma (ACP)
Description: 10ml of patient's own venous blood is aspirated. ACP (1ml) (extracted from centrifuged venous sample), with additional calcium chloride is then injected into the tendon-bone junction and adjacent area under guided ultrasound.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively
Study NCT01414764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (1ml saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively
Study NCT02499692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNERGYTM Coronary Stent System
Description: SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System
Study NCT03067493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neo-MASCT
Description: Patients assigned to Neo-MASCT treatment will receive 18 cycles of neo-MASCT (6 courses), with one cycle every month for the first year and one cycle every 2 months for the second year. Each cycle includes one DCs subcutaneous injection and one CTLs infusion.
Study NCT00121394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine vaginal and infant wash
Study NCT00386477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal cleansing before cesarean delivery
Description: Cleansing vagina with 1% betadine scrub before cesarean.
Study NCT02830204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitral Valve Replacement with Sapien3
Description: subjects with surgical MVR with Sapien3
Study NCT03342040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic ventral hernia repair with TAP block
Description: Transverse abdominis plane block is given under ultrasound guidance during laparoscopic ventral hernia surgery
Study NCT03342040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ventral hernia repair without TAP block
Description: No block administered during Laparoscopic ventral hernia surgery
Study NCT03421743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled molgramostim
Description: 300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
Study NCT03421743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antimycobacterial regimen
Description: Multidrug NTM guideline-based antimycobacterial regimen
Study NCT00431951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-246
Description: 250 mg, 400 mg or 800 mg capsules given once daily for 21 days
Study NCT00431951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules to match experimental drug
Study NCT02775331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shift planning with self-rostering and shift ergonomics
Description: Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
Study NCT00635609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate (Doryx)
Description: 150mg/day, oral, delayed release tablets
Study NCT00635609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline hyclate
Description: 100 mg/day, oral, tablets, immediate release
Study NCT04290143 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colored healing water
Description: Patients will be treated with colored healing water for 20 minutes.
Study NCT04290143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo treatment (colored tap water)
Description: Patients will be treated with colored tap water for 20 minutes.
Study NCT01248442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: monthly dose of 140.000 IU of cholecalciferol orally, 3 times.
Study NCT02085512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurocognitive retraining Web Based Intervention
Description: Neurobehavioral training will be delivered through the web, with prompting for training tasks accomplished through daily emails that include a single integrated log-in system using a customized implementation with OneLogin. All training tasks have game-like features making them visually engaging, and motivating. The training tasks provide immediate feedback about performance, and are specifically designed to target circuitry critical for executive functioning (EF) and emotional reactivity.
Study NCT02775331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shift planning with shift ergonomics
Description: Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
Study NCT03455829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38
Description: CDK 4/6 inhibitor
Study NCT01248442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT02085512 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control, web-based tasks
Description: No training modules
Study NCT03455829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: EGFR TKI; 80 mg
Study NCT01707303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early ICU rehabilitation strategies
Description: Physical therapy - standard; Physical therapy, progressive resistance training for 2nd physical therapy session in Cohort II
Study NCT01939132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open label H.P. Acthar Gel
Description: Open-label H.P. Acthar Gel 80 units given subcutaneously twice weekly for 12 weeks with 12 week extension.
Study NCT02182908 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PET-Scan
Description: PET-Scan
Study NCT04412122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: In the study, kinesio taping method was applied immediately after the surgical operation. The tape was applied on one centimeter above and one centimeter below the incision site with a 25% tension in web cutting technique (Figure 1.). In order to facilitate gas passing and defecation, the tape was applied around the navel in the Y shape with a 25% tension (Figure 2). No tension was applied to the starting and ending points of the tape. Pain level was evaluated with VAS before and after 45 minutes of tape application. Pain level was evaluated by VAS on the 1st, 2nd and 3rd postoperative day. Kinesio tape remained on women for 72 hours.
Study NCT01707303 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: All typically applied hospital rehabilitative services applied in the usual fashion
Study NCT04638049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of human biofluids
Description: Feces, blood and urine: (1) shortly before, (2) during and (3) shortly after RT treatment, as well as (4) one-month post-RT